Praecis Plenaxis Risk Management Will Include Controlled Distribution
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Praecis’ risk management program for its pending prostate cancer therapy Plenaxis is being modified at FDA’s request "to include some form of controlled or managed distribution," the firm said.